Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2026	Sep. 30, 2025	Sep. 30, 2026	Sep. 30, 2025
Revenues
Total revenues	$ 793,981	$ 592,183	$ 2,243,377	$ 1,640,615
Cost and expenses
Research and development	242,433	173,412	681,206	448,917
Selling, general and administrative	333,656	308,546	988,798	885,962
Amortization of acquired intangible assets	5,700	0	17,100	0
Total cost and expenses	862,303	689,759	2,481,005	1,927,741
Loss from operations	(68,322)	(97,576)	(237,628)	(287,126)
Interest expense	(903)	(1,045)	(2,685)	(3,078)
Interest and other income, net	9,612	11,284	28,665	35,441
Loss before income taxes	(59,613)	(87,337)	(211,648)	(254,763)
Income tax benefit (expense)	(299)	(207)	(324)	(655)
Net loss	(59,912)	(87,544)	(211,972)	(255,418)
Unrealized gain (loss) on available-for-sale securities, net of tax and foreign currency translation adjustment	(20)	100	130	157
Comprehensive loss	$ (59,932)	$ (87,444)	$ (211,842)	$ (255,261)
Net loss per share (Note 14):
Basic (in dollars per share)	$ (0.42)	$ (0.64)	$ (1.48)	$ (1.88)
Diluted (in dollars per share)	$ (0.42)	$ (0.64)	$ (1.48)	$ (1.88)
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic (in shares)	144,067	137,187	142,959	136,181
Diluted (in shares)	144,067	137,187	142,959	136,181
Foresight Diagnostics, Inc.
Cost and expenses
Amortization of acquired intangible assets	$ 5,707	$ 0	$ 17,123	$ 0
Product revenues
Revenues
Total revenues	789,981	590,197	2,231,778	1,634,660
Cost and expenses
Cost of revenues	279,636	207,253	791,435	591,397
Licensing and other revenues
Revenues
Total revenues	4,000	1,986	11,599	5,955
Cost and expenses
Cost of revenues	$ 871	$ 548	$ 2,443	$ 1,465